This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Companion Diagnostics Market, 2012-2023

7. ANALYSIS OF THERANOSTICS MARKET: STAKEHOLDERS AND BUSINESS MODELS7.1. Chapter Overview7.2. Theranostics Market in 20127.3. Stakeholders in the Market7.3.1. Theranostic Development Agencies7.3.1.1. Pharmaceutical Company7.3.1.1.1. Traits a Pharmaceutical Company Looks for in a Companion Diagnostics Developer7.3.1.1.2. Pharmaceutical Company Business Models7.3.1.2. The Companion Diagnostic Developer7.3.1.2.1. Companion Diagnostic Company Business Models7.3.1.3. Recent Partnerships7.3.2. Testing Laboratories7.3.3. Contract Research Organisations (CROs)7.3.4. Regulatory Authorities7.3.5. Buyers/Target Audience7.3.6. Payers

8. NEED FOR COMPANION DIAGNOSTICS8.1. Low Drug Efficacy Rates8.2. Poor Drug Compliance8.3. High Cost of Drug Development8.4. Phase II and III Drug Failures8.5. Drug Recalls8.6. Tools and Technologies Enabling the Move to Companion Diagnostics8.6.1. Growing Significance of Biomarkers8.6.2. Reducing Costs of Genome Sequencing8.7. SWOT Analysis8.7.1. Strengths8.7.2. Weaknesses8.7.3. Opportunities8.7.4. Threats

9. CONCLUSIONS9.1. Companion Diagnostics: An Emerging Market9.2. Co-Development and Approval of Companion Diagnostic will be the Preferred Route of Development9.3. Key Driving Factors9.4. Concluding Remarks

List of FiguresFIGURE 2.1 Segments of Personalised Medicine DiagnosticsFIGURE 2.2 Biomarker to Companion DiagnosticsFIGURE 3.1 NME Approved by the FDA, 2011 - With or Without Biomarker (%)FIGURE 3.2 Companion Drugs Market, 2012 - By Leading Drugs (USD MM, %)FIGURE 3.3 Companion Drugs Market, 2012 - By Leading Indication (USD MM, %)FIGURE 3.4 Companion Drugs Market, 2012 - by Leading Companies (USD MM, %)FIGURE 3.5 HER2 Expression in Breast Cancer Patients (%)FIGURE 3.6 Herceptin Sales, 1998 - 2012 (USD MM)FIGURE 3.7 EML4-ALK Expression in Non Small Cell Lung Cancer Patients (%)FIGURE 3.8 Timeline for Development of Xalkori and Companion Diagnostic, 2005 - CurrentFIGURE 3.9 BRAF V600E Expression in Metastatic Melanoma Patients (%)FIGURE 3.10 Timeline for Development of Zelboraf and Companion Diagnostic, 2006 - CurrentFIGURE 3.11 Iressa Sales, 2005 - 2012 (USD MM)FIGURE 4.1 In Vitro Diagnostics Market - by Intent of Use (USD BN, %)FIGURE 4.2 Personalised Medicine Diagnostics Market, 2012 - by Type (USD MM, %)FIGURE 4.3 Revenues Generated by Services and Sales of Companion Diagnostic Products, 2012 (USD MM, %)FIGURE 4.4 Companion Diagnostics Market, Short-Mid Term Forecast: 2013-2018 (USD MM)FIGURE 4.5 Companion Diagnostics Market, Long Term Forecast: 2019-2023 (USD MM)FIGURE 4.6 Molecular and Tissue Diagnostics Market, 2012 (USD BN, %)FIGURE 4.7 Molecular Diagnostics Market, 2012 - by Leading Companies (%)FIGURE 4.8 Molecular and Tissue Diagnostics Market, 2012-2018 (USD BN)FIGURE 5.1 Companion Diagnostics Market, 2012 - by Regions (USD MM, %)FIGURE 5.2 European Companion Diagnostics Market, 2012 - by Countries (USD MM, %)FIGURE 5.3 Number of KRAS Tests Performed in France, 2007-2010FIGURE 5.4 Number of EGFR Tests Performed in France, 2008-2011FIGURE 5.5 Number of HER2, KRAS, EGFR and KIT Tests Performed in England, 2010 - 2011FIGURE 5.6 Number of EGFR Tests Performed in the UK, August 2009 - July2010FIGURE 5.7 Companion Diagnostics Market, Short-Mid Term Forecast: 2012-2018, by Leading Countries (USD MM)FIGURE 5.8 Companion Diagnostics Market, Long Term Forecast: 2019-2023, by Leading Countries (USD MM)FIGURE 6.1 Abbott Laboratories Sales, 2012 - by Business Segments (USD MM, %)FIGURE 6.2 Abbott Laboratories Sales, 2012 – Diagnostics Segment (USD MM, %)FIGURE 6.3 Qiagen Sales, 2012 - by Business Segments (USD MM, %)FIGURE 6.4 Qiagen Personalised Healthcare Sales, 2012 (USD MM, %)FIGURE 6.5 Agilent Technologies Sales, 2012 - by Business Segments (USD MM, %)FIGURE 6.6 Roche Group Sales, 2012 - by Business Segments (USD MM, %)FIGURE 6.7 Roche Diagnostics Sales, 2012 - by Segments (USD MM, %)FIGURE 7.1 Theranostic Sales, 2012 - by Segments (USD MM, %)FIGURE 7.2 Stakeholders in the Theranostics MarketFIGURE 7.3 Business Models for Companion Diagnostic DevelopmentFIGURE 8.1 Efficacy Rate of Drugs (%)FIGURE 8.2 Reasons for Drug Failure in Phase II of Clinical Trials, 2008-2010FIGURE 8.3 Reasons for Drug Failure in Phase III of Clinical Trials, 2007-2010FIGURE 8.4 Pipeline Drugs Attached with Biomarkers - by Phase of Development (%)FIGURE 8.5 Cost of Genome Sequencing (USD) - per Megabase, 2001-2012

List of TablesTABLE 3.1 Companion Drugs Approved by the FDA,TABLE 3.2 Companion Drugs Approved by the EMATABLE 4.1 List of Marketed Companion Diagnostic Tests, 2012TABLE 4.2 List of Companion Diagnostics in PipelineTABLE 5.2 Proposed Classification of IVDsTABLE 5.3 List of Companion Diagnostics Tests Conducted in France, 2012TABLE 5.4 NICE Approved Oncology Drugs Associated with Companion DiagnosticsTABLE 5.5 Japan's Population Over 65 - 2010, 2015 and 2020 ('000, %)TABLE 7.1 Deals and Collaborations for Companion Diagnostic Development, January 2011 - PresentTABLE 8.1 Drug Recalls from the US Market, 1996-2007TABLE 8.2 SWOT Analysis of Companion Diagnostics MarketTABLE 10.1 List of New Molecular Entities (NMEs) Approved with Pharmacogenomic BiomarkerTABLE 10.2 Companion Drugs Market, 2012 - by Leading Drugs (USD MM)TABLE 10.3 Companion Drugs Market, 2012 - by Leading Indication (USD MM, %)TABLE 10.4 Companion Drugs Market, 2012 - by Leading Companies (USD MM, %)TABLE 10.5 Herceptin Sales, 1998 - 2012 (USD MM)TABLE 10.6 Iressa Sales, 2005 - 2012 (USD MM)TABLE 10.7 In Vitro Diagnostics Market, 2012 - by Intent of Use (USD BN, %)TABLE 10.8 Personalised Medicine Diagnostics Market, 2012 - by Type (USD MM, %)TABLE 10.9 Revenues Generated by Service Providers and Sales of Companion Diagnostic Products, 2012 (USD MM, %)TABLE 10.10 Companion Diagnostics Market, Short-Mid Term Forecast: 2013-2018 (USD MM)TABLE 10.11 Companion Diagnostics Market, Long Term Forecast: 2019-2023 (USD MM)TABLE 10.12 Molecular and Tissue Diagnostics Market, 2012 (USD BN, %)TABLE 10.13 Molecular and Tissue Diagnostics Market, 2012-2018 (USD BN)TABLE 10.14 Companion Diagnostics Market, 2012 - by Leading Regions (USD MM, %)TABLE 10.15 European Companion Diagnostics Market, 2012 - by Leading Countries (USD MM, %)TABLE 10.16 Number of KRAS Tests Performed in France, 2007-2010TABLE 10.17 Number of EGFR Tests Performed in France, 2008-2011TABLE 10.18 Number of HER2, KRAS, EGFR and KIT Tests Performed in England, 2010 - 2011TABLE 10.19 Companion Diagnostics Market, Short-Mid Term Forecast: 2012-2018, by Leading Countries (USD MM)TABLE 10.20 Companion Diagnostics Market, Long Term Forecast: 2019-2023, by Leading Countries (USD MM)TABLE 10.21 Abbott Laboratories Sales, 2012 - by Business Segments (USD MM, %)TABLE 10.22 Abbott Laboratories Sales, 2012 – Diagnostics Segments (USD MM, %)TABLE 10.23 Qiagen Sales, 2012 - by Business Segments (USD MM, %)TABLE 10.24 Qiagen Personalised Healthcare Sales, 2012 (USD MM, %)TABLE 10.25 Agilent Technologies Sales, 2012 - by Business Segments (USD MM, %)TABLE 10.26 Roche Group Sales, 2012 - by Business Segments (USD MM, %)TABLE 10.27 Roche Diagnostics Sales, 2012 - by Segments (USD MM, %)TABLE 10.28 Theranostic Sales, 2012 - by Segments (USD MM, %)TABLE 10.29 Cost of Genome Sequencing (USD) - per Megabase, 2001-2012

The following companies have been mentioned in this report:1. A&G Pharmaceutical2. AB Science3. Abbott Molecular4. Abkine Pharmaceutical5. Aeterna Zentaris6. Amgen7. Amoy Diagnostics Co.8. Ariad Pharmaceuticals9. AstraZeneca10. Asuragen11. Bayer12. Beckman Coulter13. Biodesix14. BioGenex Laboratories15. BioMérieux16. Biotage17. Boehringer Ingelheim18. Bristol Myers Squibb19. Celgene20. Cell Signaling Technology (CST)21. Celldex Therapeutics22. Cephalon23. ChemGenX Pharmaceuticals24. Clovis Oncology25. Daiichi Sankyo26. Dako27. Eisai28. Eli Lilly29. Endocyte30. Epic Sciences31. Epizyme32. ERYtech Pharma33. Evotec34. Foundation Medicine35. Genentech36. Genomic Health37. Genzyme Genetics38. GlaxoSmithKline39. Imclone40. Immunex41. Insight Genetics42. Inverness Medical Innovations43. Invivoscribe Technologies44. Ipsen45. Janssen Biotech46. Lab2147. LabCorp48. Leica Biosystems49. Life Technologies Corporation50. Luminex Corporation51. MDx Health52. Merck53. Millennium54. Molecular MD55. Monogram Biosciences56. Myriad Genetics57. Neovacs58. Nodality59. Novartis60. OncoMed Pharmaceuticals61. Ortho-Clinical Diagnostics62. OSI Pharmaceuticals63. Personal Genome Diagnostics64. Pfizer65. Pharma Mar66. Plexxikon Inc67. Psynova Neurotech68. Qiagen69. Roche Laboratories70. Rules-Based Medicine71. Saladax Biomedical72. Sanofi73. Seattle Genetics74. Shire75. Siemens76. Signature Diagnostics77. Sirius Genomics78. Skuldtech79. Syndax Pharmaceuticals80. TcLand Expression81. Tesaro82. Tocagen83. Tragara Pharmaceuticals84. Transgene85. Transgenomic86. TIB MolBiol87. UCB Pharma88. Unidex89. Validus90. Ventana Medical Systems91. Vertex Pharmaceuticals92. ViiV Healthcare93. Xdx94. Xenon Health

The following organisations have been mentioned in this report:1. Centers for Medicare and Medicaid Services (CMS)2. Committee for Medicinal Products for Human Use (CHMP)3. European Medicines Agency (EMA)4. Food and Drug Administration (FDA)5. Forbes6. Jichi Medical University7. National Human Genome Research Institute (NHGRI)8. National Institute for Clinical Excellence (NICE)9. Pharmaceutical Research and Manufacturers of America (PhRMA)

To order this report:: Companion Diagnostics Market, 2012-2023

__________________________Contact Clare: clare@reportlinker.comUS:(339) 368 6001Intl:+1 339 368 6001

SOURCE Reportlinker

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
4 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,131.97 +100.83 0.59%
S&P 500 1,998.98 +14.85 0.75%
NASDAQ 4,552.7590 +33.8570 0.75%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs